Convatec Group Plc
(“Convatec” or “the Company”)
Director updates
London, UK, 3 November 2026 – Convatec today announces the following Board changes.
Jill McConnell has been appointed Convatec’s Chief Financial Officer (Designate) from 1 January 2027, becoming CFO from 1 March 2027. See Chief Financial Officer succession arrangements announcement published today for further details.
Fiona Ryder will remain Chief Financial Officer until the end of February 2027, when she will leave the business.
Brian May has been appointed as Senior Independent Director, succeeding Margaret Ewing, effective 3 November 2026.
Tobias Hestler has been appointed as Chair of the Audit and Risk Committee, also succeeding Margaret Ewing, effective 3 November 2026.
Margaret Ewing will remain a member of the Board, Audit and Risk Committee and Nomination Committee to support this transition, and will continue to fulfil her role as Non-Executive Director until she retires from the Board on or before the Company’s next Annual General Meeting.
Dr John McAdam, Chair of the Board, said: “On behalf of the Board, I would like to express our deepest thanks to Margaret for her considerable contribution as Senior Independent Director and Chair of the Audit and Risk Committee. Since 2017, Margaret has brought significant experience, insight and judgement to the Board, and her leadership and counsel have been greatly valued.
“I am very pleased to welcome Jill to the Board next year and look forward to working with her when she becomes CFO. I would also like to thank Fiona Ryder, who, as recently announced, will stand down from the Board and as CFO at the end of February 2027. Fiona has made a substantial contribution to the business through its turnaround, for which we are very grateful.
“I am pleased that Margaret will continue to serve on the Board to support this transition, and I look forward to working with Tobias and Brian in their new roles.”
This announcement is made in accordance with Listing Rule 6.4.6.
Enquiries
Analysts & investors: ir@convatec.com
Media: mediarelations@convatec.com
Notes
Director biographies, skills and experience can be viewed here.
Convatec Group Plc’s LEI code is 213800LS272L4FIDOH92
About Convatec
Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With over 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard-to-heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2025 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more, please visit http://www.convatecgroup.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.